301 related articles for article (PubMed ID: 22162978)
1. Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.
Alkhouri N; Carter-Kent C; Elias M; Feldstein AE
Clin Lipidol; 2011 Jun; 6(3):305-314. PubMed ID: 22162978
[TBL] [Abstract][Full Text] [Related]
2. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
Choudhary NS; Duseja A
J Clin Exp Hepatol; 2019; 9(4):506-514. PubMed ID: 31516267
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease.
Akhtar DH; Iqbal U; Vazquez-Montesino LM; Dennis BB; Ahmed A
J Clin Transl Hepatol; 2019 Dec; 7(4):362-370. PubMed ID: 31915606
[TBL] [Abstract][Full Text] [Related]
4. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease.
Iqbal U; Perumpail BJ; Akhtar D; Kim D; Ahmed A
Medicines (Basel); 2019 Mar; 6(1):. PubMed ID: 30889791
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease and the heart in children and adolescents.
Pacifico L; Chiesa C; Anania C; De Merulis A; Osborn JF; Romaggioli S; Gaudio E
World J Gastroenterol; 2014 Jul; 20(27):9055-71. PubMed ID: 25083079
[TBL] [Abstract][Full Text] [Related]
6. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Long MT; Noureddin M; Lim JK
Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease in South Asia.
Pati GK; Singh SP
Euroasian J Hepatogastroenterol; 2016; 6(2):154-162. PubMed ID: 29201749
[TBL] [Abstract][Full Text] [Related]
8. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
[TBL] [Abstract][Full Text] [Related]
13. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
Crespo M; Lappe S; Feldstein AE; Alkhouri N
Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
[TBL] [Abstract][Full Text] [Related]
14. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.
Stepanova M; Younossi ZM
Clin Gastroenterol Hepatol; 2012 Jun; 10(6):646-50. PubMed ID: 22245962
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease.
Nobili V; Alisi A; Newton KP; Schwimmer JB
Gastroenterology; 2016 Jun; 150(8):1798-810. PubMed ID: 27003600
[TBL] [Abstract][Full Text] [Related]
16. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?
Maurantonio M; Ballestri S; Odoardi MR; Lonardo A; Loria P
Arch Med Res; 2011 Jul; 42(5):337-53. PubMed ID: 21843565
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Risk in Children with Nonalcoholic Fatty Liver Disease (NAFLD).
Chociej AB; Wasilewska N; Flisiak-Jackiewicz M; Lebensztejn D
Curr Pediatr Rev; 2020; 16(4):294-297. PubMed ID: 33038914
[TBL] [Abstract][Full Text] [Related]
19. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease.
Finney AC; Das S; Kumar D; McKinney MP; Cai B; Yurdagul A; Rom O
Front Cardiovasc Med; 2023; 10():1116861. PubMed ID: 37200978
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease and non-liver comorbidities.
Manikat R; Nguyen MH
Clin Mol Hepatol; 2023 Feb; 29(Suppl):s86-s102. PubMed ID: 36603574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
